The Journal of Pain
Volume 7, Issue 10 , Pages 735-746, October 2006

Design and Characterization of a Noncompetitive Antagonist of the Transient Receptor Potential Vanilloid Subunit 1 Channel With In Vivo Analgesic and Anti-inflammatory Activity

  • Carolina García-Martínez

      Affiliations

    • Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain
  • ,
  • Asia Fernández-Carvajal

      Affiliations

    • Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain
  • ,
  • Belen Valenzuela

      Affiliations

    • División de Farmacia y Tecnología Farmacéutica, Dpto Ingeniería, Universidad Miguel Hernández, Alicante, Spain
  • ,
  • Ana Gomis

      Affiliations

    • Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Alicante, Spain
  • ,
  • Wim Van Den Nest

      Affiliations

    • DiverDrugs, SL, Gavà, Barcelona, Spain
  • ,
  • Stefano Ferroni

      Affiliations

    • Department of Human and General Physiology, University of Bologna, Bologna, Italy
  • ,
  • Cristina Carreño

      Affiliations

    • DiverDrugs, SL, Gavà, Barcelona, Spain
  • ,
  • Carlos Belmonte

      Affiliations

    • Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Alicante, Spain
  • ,
  • Antonio Ferrer-Montiel

      Affiliations

    • Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain
    • Corresponding Author InformationAddress reprint requests to Antonio Ferrer-Montiel, MD, Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Ed. Torregaitán, Av de la Universidad s/n, 03202 Elche (Alicante), Spain.

Received 1 December 2005; received in revised form 14 March 2006; accepted 27 March 2006. published online 10 May 2006.

Abstract 

Vanilloid receptor subunit 1 (TRPV1) is an integrator of physical and chemical stimuli in the peripheral nervous system. This receptor plays a key role in the pathophysiology of inflammatory pain. Thus, the identification of receptor antagonists with analgesic and anti-inflammatory activity in vivo is an important goal of current neuropharmacology. Here, we report that [L-arginyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl) glycinamide (H-Arg-15-15C) is a channel blocker that abrogates capsaicin and pH-evoked TRPV1 channel activity with submicromolar activity. Compound H-Arg-15-15C preferentially inhibits TRPV1, showing marginal block of other neuronal receptors. Compound H-Arg-15-15C acts as a noncompetitive capsaicin antagonist with modest voltage-dependent blockade activity. The compound inhibited capsaicin-evoked nerve activity in afferent fibers without affecting mechanically activated activity. Notably, administration of compound H-Arg-15-15C prevented the irritant activity of a local administration of capsaicin and formalin and reversed the thermal hyperalgesia evoked by injection of complete Freund’s adjuvant. Furthermore, it attenuated carrageenan-induced paw inflammation. Compound H-Arg-15-15C specifically decreased inflammatory conditions without affecting normal nociception. Taken together, these findings demonstrate that compound H-Arg-15-15C is a channel blocker of TRPV1 with analgesic and anti-inflammatory activity in vivo at clinically useful doses and substantiate the tenet that TRPV1 plays an important role in the etiology of chronic inflammatory pain.

Perspective

This study reports the design of a potent TRPV1 noncompetitive antagonist that exhibits anti-inflammatory and analgesic activity in preclinical models of acute and chronic pain. This compound is a lead for analgesic drug development.

Key words:  Vanilloid receptor subunit 1 , inflammatory pain , capsaicin , formalin , analgesic

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the Ministerio de Educacion Ciencia y Deporte (SAF 2003/0509), La Fundación Ramón Areces (01/08-500), and Generalitat Valenciana (GV04B-0398) to A.F.M., PROFIT-090000-2001-70 and CDTI-03-006 (Ministerio de Industria) to DiverDrugs, SL.

PII: S1526-5900(06)00686-9

doi:10.1016/j.jpain.2006.03.008

The Journal of Pain
Volume 7, Issue 10 , Pages 735-746, October 2006